For example, Vaskivuo et al. observed low levels of BCL2 expression in grade I endometrial carcinomas and very low levels or no BCL2 expression in grade II and III endometrial carcinomas, respectively [14], suggesting that the BCL2 g ene is a valuable predictor of disease progression [15]. This evidence concerns the gene BCL2 and endometrial carcinoma.